Longevity Biotech Report Landing Page – 1 – DLT | Decoding Longevity Trends – Longevity.Technology

Register with a work email to read the Longevity Biotech Report in full.
Only fill in if you are not human
Built on deliberately conservative assumptions — and benchmarked against statins and GLP-1s.
Neither FDA nor EMA recognises gerotherapeutics yet. Three independent clocks now point to the same year.
A year’s revenue from assets that exist right now, this is the value sitting in today’s pipelines.
2025 life-sciences M&A was up 81%. The patent cliff is widening every year to 2032.
The race is on.
The ROI has never been more compelling
Report supported by MuseCell Innovations. Editorial control rests with Longevity.Technology.
Is it really free?
What exactly do I get?
We need the asset-level data for our own models.
NEWS
DATA
PODCAST
CLINICS
Longevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643
First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest. First Longevity Limited does not give advice on the risks of investment and is not authorised to carry out investment business under the Financial Services and Markets Act 2000 (“FSMA”).
The content on this website has not been approved by an authorised person within the meaning of FSMA, for the purposes of section 21 of FSMA and reliance on information on this website for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of their property or other assets involved.
Users of this website should not treat its contents as constituting advice relating to legal, taxation or investment matters and are advised to consult their own professional advisers authorised under FSMA who specialize in advising on such matters.

source